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Heat shock protein 20 (HSP20) is a novel substrate for protein kinase
D1 (PKD1)
Yuan Yan Sin and George S. Baillie*
Institute of Cardiovascular and Medical Sciences, CMVLS, University of Glasgow, Glasgow, UK
Heat shock protein 20 (HSP20) has cardioprotective qualities, which are triggered by PKA phosphorylation. PKD1 is also a binding partner
for HSP20, and this prompted us to investigate whether the chaperone was a substrate for PKD1. We delineate the PKD1 binding sites on
HSP20 and show for the ﬁrst time HSP20 is a substrate for PKD1. Phosphorylation of HSP20 by PKD1 is diminished by pharmacological
or siRNA reduction of PKD1 activity and is enhanced following PKD1 activation. Our results suggest that both PKA and PKD1 can both
phosphorylate HSP20 on serine 16 but that PKA is the most dominant. Copyright © 2015 John Wiley & Sons, Ltd.
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INTRODUCTION
Heat shock protein 20 (HSP20), also referred to as P20 or
HSPB6, is ubiquitously expressed in a number of tissues with
the highest levels in the heart.1 HSP20 is inactive or partially
active under physiological conditions and converts to an active
phosphorylated state upon modulation by stress kinases.2,3
The phosphorylation of HSP20 is thought to be a key step in
certain neurohormonal signalling pathways and is particularly
important in the myocardial β-adrenergic signalling cascade
where it acts as an intermediate in a variety of cardioprotective
responses to injuries arising from β-agonist induced hypertro-
phy and ischemia/reperfusion.4,5 The cardioprotecive signal-
ling pathways activated by phospho-HSP20 stem from the
promotion actin binding by the chaperone6 and the inhibition
of P38, JNK,7 caspase 3 and NF-KB pathways.8 The
phosphorylation of HSP20 normally occurs in response to
increased levels of cyclic nucleotide second messengers that
activate kinases such as cAMP-dependent protein kinase A
(PKA) and cGMP-dependent protein kinase G (PKG).9 To
date, most assumptions about the signiﬁcance of HSP20
phosphorylation have been made around serine 16, which is
located within the sequence motif (RRXS), a characteristic
consensus motif for both PKA and PKG.10,11
Recently, we have identiﬁed protein kinase D1 (PKD1) as
a novel partner for HSP20 using high-density ProtoArray
analysis.12 Investigation into the physiological function of
the PKD–HSP20 interaction was facilitated by a novel
disruptor peptide, which acted to disassemble the complex
and reveal its role in pathological cardiac growth and cardiac
remodelling. Being a major PKD isoform in the heart, PKD1
has been implicated in the phosphorylation of several sarco-
meric proteins, such as cardiac troponin I (TnI), cardiac
myosin binding protein C and telethonin to regulate myocar-
dial contractility.13 PKD1 also regulates class II histone
deacetylases (HDACs), which are known as pro-hypertrophy
transcription regulators.14 Notably, these putative PKD1
substrates commonly contain a well-deﬁned phosphorylation
motif in the sequence (LXRXXS/T), where an aliphatic
amino acid (Ile/Leu/Val) and a basic amino acid (Arg) are
located at the 5 and 3 positions relative to the serine
target site, respectively.15,16 Here, we show for the ﬁrst time
that HSP20 is a novel substrate for PKD1 and that the
putative phospho-site is Ser16 (also the PKA and PKG sites).
MATERIALS AND METHODS
Antibodies and reagents
Anti-HSP20 antibody (#07-490) was purchased fromMillipore.
Anti-HSP20-phospho-Ser16 (#ab58522) and α-tubulin
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(#ab-18251) were purchased from Abcam. Anti-PKD1
(#2052) and anti-phospho-PKD (auto-phosphorylation site
at Ser916, #2051) antibodies were purchased from Cell
Signaling. Horseradish peroxidase-conjugated goat anti-
rabbit and anti-mouse secondary antibodies, and PKA
inhibitor KT5720 were purchased from Sigma. Anti-
RACK1 antibody (#sc-17754) was purchased from
Santa Cruz. PKD1–HSP20 disruptor peptide (disr pept)
(GRDVAIKIIDKLRFPTKQESQLRNE) and control pep-
tide (cont pept) (GAAVAIKIIAKLRFPTKQESQLRNE)
were synthesised by GenScript and included an N-terminal
stearoyl group (CH3(CH2)16COOH), making them cell
permeable. PKD1 activator bryostatin 1 and inhibitor
Go6976 were purchased from Calbiochem. For cell studies,
peptides/compounds were dissolved in dimethyl sulfoxide
(DMSO) (Sigma) and used at a ﬁnal concentration of
DMSO≤ 0·1% (v v1).
SPOT synthesis of peptides and overlay experiments
This was performed as described by us in detail elsewhere.17
Cell culture and transfection
Neonatal rat cardiomyocytes were cultured as previously
described.18 DNA plasmid constructs used for transfection
included V5-HSP20 in pDEST vector and GFP-PKD1 in
pEF-BOS vector. siRNA-mediated PKD1 knockdown in
cardiomyocytes was carried out using a siRNA transfection
kit speciﬁc for rat PKD1 (Santa Cruz, #sc-36260) according
to the manufacturer’s protocol.
Western blotting
Cellular extract proteins were resolved by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS–PAGE)
and transferred onto nitrocellulose membranes for Western
blotting. Immunoreactive proteins were detected using
appropriate antibodies and visualised by enhanced chemilu-
minescence detection (Pierce). Quantiﬁcation of the band
intensity was accomplished by densitometry using Quantity
One 1-D software (Bio-Rad).
In vitro phosphorylation of His-HSP20
A range of puriﬁed His-HSP20 concentration (0·5–2μg) was
incubated with 1·0 gml1 or without active PKD1 protein
(Abcam) in PKD phosphorylation buffer [20mM Tris–HCl;
pH7·5, 10mM MgCl2, 0·5mM CaCl2, 1mM dithiothreitol
(DTT), 0·2mgml1 bovine serum albumin (BSA)] supple-
mented with 100μM adenosine-5′-triphosphate (ATP) for
1h at 30 °C with agitation. The phosphorylated protein was
then subjected to SDS–PAGE and immunoblotted with an
anti-phospho-HSP20 (Ser 16) antibody.
In vitro phosphorylation of peptide array
Peptide arrays corresponding to the entire sequence of
HSP20 (25mers, sequentially shifted by ﬁve amino acids)
were constructed as published previously5. Phosphorylation
of HSP20 peptide array was carried out to identify phos-
phorylation site(s) by PKD1. Brieﬂy, the peptide array
membrane was soaked in 100% ethanol to activate it and
washed with Tris-buffered saline and Tween 20, followed
by overnight blocking in 5% phosphoblocker containing
0·5mM DTT and 1mM ATP at 4 °C. The membrane was
then reacted with PKD1 phosphorylation buffer (20mM
Tris–HCl; pH7·5, 10mM MgCl2, 0·5mM CaCl2, 1mM
DTT, 0·2mgml1 BSA, 1mM ATP) supplemented with
10μg of active PKD1 (Abcam) and 5μCi (0·185MBq) of
[γ-32P] ATP EasyTides (Perkin Elmer, UK) for 30min at
37 °C with gentle agitation. After the phosphorylation
reaction, the membrane was washed extensively with 1M
NaCl followed by 5% H3PO4 and ﬁnally ethanol. The
membrane was air dried and placed in intensifying screen
cassette (Kodak BioMax MS, Carestream Health, Inc.) for
a week before developing using the Kodak® X-Omat Model
2000 processor.
Statistical analysis
Values are presented as mean ±SEM from at least three
independent experiments. Statistical signiﬁcances between
groups were determined by the use of Student’s t-test or
one-way ANOVA tests followed by post hoc Tukey’s tests.
Values were considered signiﬁcant if p< 0·05. Where
representative immunoblots were shown, similar data were
obtained n≥ 3 times.
RESULTS
HSP20 phosphorylation on serine 16 is inﬂuenced by PKD1
activity
As a sequence analysis of HSP20 showed it to contain a suitable
consensus for PKD1 phosphorylation (S10WLRRXSAPLP20),
we sought to evaluate whether the heat shock protein could
be phosphorylated by PKD1. We used two experimental
approaches to examine the effect of PKD1 activity on the
phosphorylation level of HSP20 at serine 16. Firstly, we
utilised pharmacological inhibition/activation of the kinase.
Cells were treated with activator bryostatin 1 (10 nM)19 or
inhibitor Go6976 (20 nM).20 PKD1 activation was then
assessed using an anti-phospho-PKD1 (auto-phosphoryla-
tion site at Ser916) antibody that detects only the active
form of the kinase.21 Our results showed that PKD1
activation was signiﬁcantly elevated following stimulation
with bryostatin 1 (p< 0·05) and diminished signiﬁcantly
(p<0·01) after treatment with Go6976. Interestingly, the
phosphorylation of HSP20 increased along with activation
of PKD1 and converse inhibition of PKD1 decreased
HSP20 phosphorylation (Figure 1A). Secondly, we
undertook a loss-of-function approach to conﬁrm the direct
effect of PKD1 activation on HSP20 phosphorylation in an
endogenous cell system. The transfection of neonatal rat
cardiomyocytes with PKD1 siRNA markedly suppressed
endogenous PKD1 expression, whereas non-speciﬁc control
siRNA had no effect (Figure 1B). In a correlation with
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PKD1 silencing, there was a profound reduction in the
phosphorylation level of HSP20 (Ser16). This reduction in
phospho-HSP20 was not a result of ﬂuctuating total
endogenous HSP20 expression, which remained unchanged
following PKD1 silencing (Figure 1B). Taken together,
these data suggest that HSP20 phosphorylation at serine 16
can be inﬂuenced by PKD1 activity.
Mapping PKD binding and phosphorylation sites on HSP20
In an attempt to map the binding site of PKD1 on full-length
HSP20, we used peptide array, a technique previously
utilised by us to pinpoint the interaction sites between
HSP20 and PDE4.5 Results revealed overlapping binding
regions in the WDPF and α-crystallin domains (Figure 2A).
Alanine scanning peptide arrays of residues 6–30 and
96–120 identiﬁed a number of key amino acids that are
potentially involved in the HSP20–PKD1 interaction
(Figure 2B). Speciﬁcally, in an alanine substituted pep-
tide array encompassing amino acids P6-D30 of HSP20,
a loss of binding upon substitution of Arg11,12 with
alanine and Ala13,15 with aspartic acid was observed.
Interestingly, these amino acids form the domain sur-
rounding Ser16 (RRApSAP), a site which is similar to
the phospho-motif of the AGC kinase subfamily (PKA,
PKG and PKC).7 An in vitro phosphorylation assay
carried out on HSP20 peptide arrays using [γ-32P-ATP]
revealed an optimal putative PKD1 phosphorylation site
at Ser16 (Figure 2C). Interestingly, this site falls within
the minimal PKD recognition motif of LXRXXS, where
an arginine is normally located at the 3 position. As
reported previously, well-known substrates of PKD1 such
as HSP27, HDAC5, and cTnI commonly conform
perfectly to this phosphorylation motif as identiﬁed
through combinatorial peptide libraries.13,14,16,22 Addition-
ally, a cold in vitro kinase assay was carried out using
Figure 1. The effect of PKD1 activity on HSP20 phosphorylation. (A)
HEK293 cells were treated with bryostatin 1 (10 nM) alone or with
Go6976 (20 nM) for the indicated times. PKD1 activation and HSP20 phos-
phorylation were monitored via immunoblotting with anti-phospho-PKD1
(Ser916), which identiﬁed a band of approximately 100 kDa and anti-
phospho-HSP20 (Ser16) antibodies, which identiﬁed a band of approxi-
mately 20 kDa. Anti-HSP20 antibody was used as loading control, which
identiﬁed a band of approximately 20 kDa. (B) siRNA-mediated knock-
down of PKD1 (but not control siRNA) attenuates HSP20 phosphorylation.
The phosphorylation state (serine 16) was monitored following PKD1
silencing. *p< 0·05, **p< 0·01
Figure 2. Identiﬁcation of PKD1–HSP20 interaction and phosphorylation
sites. (A) HSP20 is shown schematically with phosphorylation site (P),
WDPF domain (dark shaded area), conserved region (light shaded area)
and α-crystallin domain (black area). Peptide array analysis identiﬁes
PKD1 binding sites on HSP20. (B) The key residues involved in the
HSP20–PKD1 interaction are delineated using alanine scanning peptide ar-
rays where each residue is sequentially substituted by alanine (or aspartate
if residue is alanine). (C) In vitro phosphorylation assay on peptide array
using [γ-32P-ATP] revealed that HSP20 is phosphorylated at Ser16 by
PKD1. (D) In vitro kinase assay (cold) using puriﬁed His-HSP20 and
PKD1 active protein further veriﬁed HSP20 phosphorylation by PKD1
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recombinant puriﬁed His-HSP20 protein and PKD1 active
protein and then probed with HSP20 phospho-Ser16 anti-
body to validate the speciﬁcity of the phosphorylation
site. Phospho-bands were detected when active PKD1
was added. No appreciable immunoreactivity was evident
when the assay mix was devoid of PKD1 (Figure 2C).
These data support the notion that PKD1 binds directly
to HSP20 in order to phosphorylate it at serine 16.
Although no other conventional PKD sites (apart from
serine 16) exist within the HSP20 sequence, we cannot
rule out the possibility that PKD1 has the ability to
phosphorylate HSP20 at other sites.
Disruption of the PKD1–HSP20 complex reduces HSP20
phosphorylation
As our data suggest a direct interaction between HSP20 and
PKD1, we were keen to determine whether the disruption of
PKD1–HSP20 interaction affects levels of HSP20 phos-
phorylation. Using a cell permeable peptide disruptor of
the PKD1–HSP20 complex previously characterised in both
in vitro and in vivo studies,12 we observed a reduction in
HSP20 phosphorylation following peptide treatment (but
not control peptide treatment) (Figure 3A). This reduction
was not due to a variation in cardiomyocytes total PKD1
activity as measured by phospho-PKD1 (Ser916) level,
suggesting that PKD1–HSP20 interaction is required for
HSP20 phosphorylation. In light of the involvement of
HSP20 phosphorylation in mediating cardiac responses in
cultured cardiomyocytes, we also examined the effect of
PKD–HSP20 complex disruption on HSP20 phosphoryla-
tion in isoprenaline (ISO)-stimulated cardiomyocytes. Once
again, the disruptor peptide but not the control peptide
caused a signiﬁcant decrease in phospho-HSP20 levels
supporting the notion that a decrease in HSP20 phosphory-
lation level can be caused by the disruption of PKD1–
HSP20 interaction without affecting PKD1 activity
(Figure 3B). As HSP20 can be phosphorylated on serine
16 by both PKA and PKD1, we investigated whether their
combined input is needed for maximal phosphorylation.
Gratifyingly, treatment with a PKA-selective inhibitor,
KT5720, resulted in nearly 80% reduction in HSP20 phos-
phorylation, and this was further diminished upon disruption
of PKD1–HSP20 interaction in cardiomyocytes (Figure 3C).
These data are in agreement with those of the previous
work, which suggests that PKA is the dominant mediator
of HSP20 phosphorylation,23 although it is clear that
PKD1 also has a role to play in this regard. We also note that
the basal phosphorylation of HSP20 is almost ablated
following PKA inhibition, suggesting that under resting
conditions, HSP20 is phosphorylated by a pool of PKA that
can be activated by the action of basally active adenylate
cyclase.
DISCUSSION
In this study, we report for the ﬁrst time that HSP20 is a
substrate for PKD1. In identifying the binding sites and
phosphorylation site for PKD1 on HSP20, we suggest that
PKD1 binds directly to the heat shock protein to enable
phosphorylation at a PKD consensus site, which contains
serine 16. Indeed, the complex between these proteins has
previously been reported.12 However, in addition to its role
in trafﬁcking PKD1, we now show that HSP20 acts as a
substrate for the kinase. Interestingly, we identify the
PKD1 phospho-site as the one also modiﬁed by PKA and
PKG.10,11 Previous work has shown that PKD1 can
Figure 3. The effect of PKD1–HSP20 interaction on HSP20 phosphoryla-
tion. (A) Cardiomyocytes were subjected to compound treatment as indi-
cated [bryostatin 1 (10 nM), Go6976 (20 nM), control peptide (10 μM) and
PKD1–HSP20 disruptor peptide (10 μM)]. Protein lysates were subjected
to immunoblotting with antibodies that recognise phospho-PKD (Ser916)
and phospho-HSP20 (Ser16). Anti-HSP20 antibody was used as loading
control. (B) The disruption of PKD1–HSP20 interaction decreased HSP20
phosphorylation in ISO-stimulated cardiomyocytes. Cells were pre-treated
with control or disruptor peptide (10 μM) prior to 24 h ISO (10 μM) stimu-
lation. Lysates were immunoblotted with anti-phospho-HSP20 (Ser16) with
anti-HSP20 as loading control. (C) The inhibition of PKA activity (KT5720
1 μM) and disruption of PKD1–HSP20 interaction greatly decreased HSP20
phosphorylation. Immunoblots showing HSP20 phosphorylation level with
respect to different treatments (upper panel). Quantiﬁcation of immunoband
intensities was determined by densitometry and was presented as fold ratio
of phosphorylation level normalised to HSP20 ± SEM of three experiments
on different cardiomyocytes preparations. *p< 0·05, **p< 0·01
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phosphorylate the same sites as PKA on TnI13,24; therefore,
it is unsurprising that PKD1 is also capable of phosphorylat-
ing other PKA targets such as HSP20 as seen in this study.
The results outlined earlier are of particular interest in light
of previous research, which has described increased PKA
phosphorylation of HSP20 as a cardioprotective mechanism
following sustained β-adrenergic stimulation.23 This is in
contrast to our recent ﬁndings, which suggest that
cardioprotection is induced by disruption of PKD1–HSP20
complex,12 an act that should result in a reduction of HSP20
phosphorylation (as reported in this study). There are exam-
ples in the literature where different kinases can elicit opposite
effects despite phosphorylating the same residue.25,26 One
possible explanation is that the functional roles of HSP20
are associated with its phospho-Ser16 status resulting from
differential kinase activation within ‘sub-pools’ of HSP20.
This notion is supported by our ﬁnding that the combined
effect of PKA inhibition and disruption of PKD1–HSP20
complex on HSP20 phosphorylation was additive. PKA could
function in concert with PKD1 to elicit signalling changes in
response to hypertrophic stimuli. Although the functional role
of PKD1 phosphorylation of HSP20 is not a subject of this
paper, we interpret these results to suggest that HSP20 phos-
phorylation at Ser16 initiates cardioprotection in a kinase-
dependent manner, with PKA being the dominant kinase with
respect to HSP20 phosphorylation. In this regard, HSP20 may
serve as a ‘regulatory hotspot’ for two opposing signalling
cues that modulate cardiac response. The balance between
PKA and PKD1 activation is likely to prescribe the conse-
quence of a hypertrophic response. Nevertheless, how
HSP20 discriminates between PKA and PKD1 in different
settings is still unclear. Further work to elucidate the mecha-
nistic details underpinning the crosstalk between different
kinase-mediated cellular responses would shed new light on
the role(s) of HSP20 in cardiac hypertrophy.
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